Assignee
BEIJING TIDE PHARMACEUTICAL CO LTD
CN·21 granted patents·15 pending applications·55 citations·filing 2017–2025
Top patents by PatentIndex Score
36 records- 0195US11919918B2P2X3 andor P2X2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereofBEIJING TIDE PHARMACEUTICAL CO LTD·Filed 2022·Granted Mar 5, 2024·6 cites·20 claims
- 0293US11390609B2Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereofBEIJING TIDE PHARMACEUTICAL CO LTD·Filed 2018·Granted Jul 19, 2022·12 cites·28 claims
- 0393US10329282B2Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereofBEIJING TIDE PHARMACEUTICAL CO LTD·Filed 2017·Granted Jun 25, 2019·13 cites·45 claims
- 0493US10323023B2Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereofBEIJING TIDE PHARMACEUTICAL CO LTD·Filed 2017·Granted Jun 18, 2019·14 cites·71 claims
- 0591US12180243B2Receptor inhibitor, pharmaceutical composition comprising same, and use thereofBEIJING TIDE PHARMACEUTICAL CO LTD·Filed 2022·Granted Dec 31, 2024·2 cites·74 claims
- 0689US11414444B2P2X3 and/or P2X2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereofBEIJING TIDE PHARMACEUTICAL CO LTD·Filed 2018·Granted Aug 16, 2022·5 cites·15 claims
- 0786US11453690B2Receptor inhibitor, pharmaceutical composition comprising same, and use thereofBEIJING TIDE PHARMACEUTICAL CO LTD·Filed 2019·Granted Sep 27, 2022·3 cites·50 claims
- 0880US12509479B2P2X3 and/or P2X2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereofBEIJING TIDE PHARMACEUTICAL CO LTD·Filed 2024·Granted Dec 30, 2025·0 cites·17 claims
- 0979US2025066398A1Receptor inhibitor, pharmaceutical composition comprising same, and use thereofBEIJING TIDE PHARMACEUTICAL CO LTD·Filed 2024·Application pending·0 cites
- 1075US2026008769A1Solid form of diaminopyrimidine compound or hydrate thereof, preparation method therefor, and application thereofBEIJING TIDE PHARMACEUTICAL CO LTD·Filed 2025·Application pending·0 cites
- 1167US11939578B2Double-stranded RNA molecule targeting CKIP-1 and use thereofBEIJING TIDE PHARMACEUTICAL CO LTD·Filed 2021·Granted Mar 26, 2024·0 cites·14 claims
- 1265US2024293559A1SHP2 inhibitor, pharmaceutical composition containing the same and application thereofBEIJING TIDE PHARMACEUTICAL CO LTD·Filed 2024·Application pending·0 cites
- 1363US2025257086A1Egfr degradation agentBEIJING TIDE PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 1462US11155819B2Double-stranded RNA molecule targeting CKIP-1 and use thereofBEIJING TIDE PHARMACEUTICAL CO LTD·Filed 2018·Granted Oct 26, 2021·0 cites·20 claims
- 1562US2023030115A1Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereofBEIJING TIDE PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 1660US2024376086A1Solid form of rho-associated protein kinase inhibitor or solvate thereof, preparation method and use thereofBEIJING TIDE PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1758US2026083748A1Pharmaceutical composition containing meloxicam, a preparation method, and an application thereofBEIJING TIDE PHARMACEUTICAL CO LTD·Filed 2025·Application pending·0 cites
- 1857US12365665B2Solid form of diaminopyrimidine compound or hydrate thereof, preparation method therefor, and application thereofBEIJING TIDE PHARMACEUTICAL CO LTD·Filed 2020·Granted Jul 22, 2025·0 cites·25 claims
- 1957US2026076936A1Sustained-release pharmaceutical composition of sivelestat or salt thereof and preparation method thereofBEIJING TIDE PHARMACEUTICAL CO LTD·Filed 2025·Application pending·0 cites
- 2056US2025352543A1Nanocrystalline preparation of rock2 inhibitor and preparation method thereforBEIJING TIDE PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 2154US2023303534A1Preparation method for novel rho-related protein kinase inhibitor and intermediate in preparation methodBEIJING TIDE PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 2253US12485108B2Method for treating fatty liver disease and/or steatohepatitisBEIJING TIDE PHARMACEUTICAL CO LTD·Filed 2020·Granted Dec 2, 2025·0 cites·17 claims
- 2351US12595261B2P2X3 and/or P2X2/3 receptor antagonist, pharmaceutical composition containing same, and use thereofBEIJING TIDE PHARMACEUTICAL CO LTD·Filed 2020·Granted Apr 7, 2026·0 cites·6 claims
- 2450US11938222B2Pregabalin sustained release composition and method for preparing the sameBEIJING TIDE PHARMACEUTICAL CO LTD·Filed 2019·Granted Mar 26, 2024·0 cites·11 claims
- 2550US2023212160A12,4,6-tri-substituted pyrimidine compounds as atr kinase inhibitorsBEIJING TIDE PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 2650US2023285393A1Method for treating graft versus host disease caused by hematopoietic stem cell transplantationBEIJING TIDE PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 2749US12582653B2Method for treating idiopathic pulmonary fibrosisBEIJING TIDE PHARMACEUTICAL CO LTD·Filed 2020·Granted Mar 24, 2026·0 cites·13 claims
- 2848US12595263B2Pyrazolopyrimidine compound used as ATR kinase inhibitorBEIJING TIDE PHARMACEUTICAL CO LTD·Filed 2021·Granted Apr 7, 2026·0 cites·31 claims
- 2948US12544382B22, 4, 6-tri-substituted pyrimidine compound as ATR kinase inhibitorBEIJING TIDE PHARMACEUTICAL CO LTD·Filed 2020·Granted Feb 10, 2026·0 cites·17 claims
- 3048US2022211703A1Method for treating cough by using diaminopyrimidine compoundBEIJING TIDE PHARMACEUTICAL CO LTD·Filed 2020·Application pending·0 cites
- 3146US12398118B2Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and use thereofBEIJING TIDE PHARMACEUTICAL CO LTD·Filed 2019·Granted Aug 26, 2025·0 cites·13 claims
- 3246US2023312530A1Salt of rho-associated protein kinase inhibitor, solid form of the salt, preparation method for same, and uses thereofBEIJING TIDE PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 3346US2022306659A1Compound inhibiting and inducing degradation of egfr and alkBEIJING TIDE PHARMACEUTICAL CO LTD·Filed 2020·Application pending·0 cites
- 3445US12410192B2Compound for inhibiting and inducing degradation of EGFR kinaseBEIJING TIDE PHARMACEUTICAL CO LTD·Filed 2020·Granted Sep 9, 2025·0 cites·20 claims
- 3544US12459917B2Salt of diaminopyrimidine compounds, and solid form thereof, preparation method therefor and use thereofBEIJING TIDE PHARMACEUTICAL CO LTD·Filed 2020·Granted Nov 4, 2025·0 cites·16 claims
- 3643US11905274B2Receptor inhibitors, pharmaceutical compositions comprising the same and use thereofBEIJING TIDE PHARMACEUTICAL CO LTD·Filed 2019·Granted Feb 20, 2024·0 cites·44 claims
Join the waitlist — get patent alerts
Get an alert when BEIJING TIDE PHARMACEUTICAL CO LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →